US FDA has approved Sanofi's Wayrilz for thrombocytopenia
The US Food and Drug Administration, FDA, has approved Wayrilz, rilzabrutinib for adults with persistent or chronic immune thrombocytopenia who have had an insufficient response to a previous treatment.











